What is it about?
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a global health issue, which poses a huge burden to the public health care. However, existing therapeutic approaches for MASLD have been underwhelming, amplifying the urgency for innovative drug exploration. Ursolic acid has been proven to perform multiple biological activities, and our previous research has elucidated that ursolic acid exhibits dual protective capacities by modulating IGF-IR and HIF-1 signalling pathways. In this current study, we further discerned that ursolic acid could attenuate the differentiation of Th17 cells, thus ameliorating immunological cascade reactions during MASLD evolution.
Featured Image
Photo by julien Tromeur on Unsplash
Why is it important?
As a crucial component of the extracellular matrix, secreted phosphoprotein 1 (SPP1) serves as a secretory factor capable of mediating intercellular crosstalk in metabolic inflammatory responses. Hence, a profound understanding of its underlying mechanisms may pave the way for innovative therapeutic strategies.
Perspectives
This current investigation shows that apart from the canonical TGF-β/IL-6 cytokine pathway, SPP1 can also directly bind to the cell surface receptors, integrin β1 and CD44, inducing the differentiation of Th17 cells by modulating their joint downstream ERK signalling pathway.
Yiyuan Zheng
Read the Original
This page is a summary of: Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease, Clinical and Molecular Hepatology, July 2024, The Korean Association for the Study of the Liver (KAMJE),
DOI: 10.3350/cmh.2024.0047.
You can read the full text:
Contributors
The following have contributed to this page
